Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE)
The purpose of this study is to test whether the combination of the study drug abemaciclib plus adjuvant endocrine therapy improves outcomes in participants with high risk, node positive, early stage, hormone receptor positive (HR+), human epidermal receptor 2 negative (HER2-), breast cancer compared to adjuvant endocrine therapy alone.
Trial Summary
Key Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
Participant must have confirmed hormone receptor positive (HR+), human epidermal receptor 2 negative (HER2-) breast cancer
Participant must have received surgery for this breast cancer
Participant must start study treatment within 12 weeks of completing their last non-endocrine treatment
Female participant of child-bearing potential must have a negative serum pregnancy test and agree to use highly effective birth control methods
Participants Must Not:
Female participant must not be pregnant or breastfeeding
Participant must be able to swallow oral medications
Participant must not have metastatic or lymph node negative disease
Participant must not have previously received treatment with any CDK4 and CDK6 inhibitor
Participant must start study treatment within 12 weeks of completing their last non-endocrine treatment
Participant must not have received an experimental treatment in a clinical trial within the last 30 days
Lilly Trial Alerts
Clinical Trial Resources
You will complete the questionnaire on another website.YesNo